SCHEMBL7240207

SCHEMBL7240207

O=C(O)C(Cc1ccccc1)NS(=O)(=O)c1ccc([N+](=O)[O-])cc1[N+](=O)[O-]

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
MAPK1 P28482 1/20 0.56
CYP2C19 P33261 1/20 0.56
HIF1A Q16665 1/20 0.56
MMP2 P08253 8/20 0.54
MMP9 P14780 5/20 0.54
ADAMTS4 O75173 1/20 0.54
MAPT P10636 1/20 0.52
POLB P06746 1/20 0.52
HTT P42858 1/20 0.52
GUSB P08236 1/20 0.51
ADAMTS5 Q9UNA0 1/20 0.49
MMP1 P03956 1/20 0.49
MMP3 P08254 1/20 0.49
MMP7 P09237 1/20 0.49
MMP13 P45452 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7240211 1.00 ALDH1A1 (0.56) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4365696 0.94 CA2 (0.51) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL6483680 0.90 AR (0.51) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5189459 0.83 MMP2 (0.73) ALDH1A1MMP2MMP9ADAMTS4MAPT
SCHEMBL26616349 0.83 MMP2 (0.73) ALDH1A1MMP2MMP9ADAMTS4MAPT
SCHEMBL26616346 0.83 MMP2 (0.73) ALDH1A1MMP2MMP9ADAMTS4MAPT
SCHEMBL4371621 0.82 POLB (0.49) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL2273345 0.80 MMP2 (0.61) ALDH1A1MMP2MMP9ADAMTS4MAPT
SCHEMBL12157354 0.79 POLB (0.46) ALDH1A1MAPK1MMP2MMP9MAPT
SCHEMBL1333933 0.79 CRHBP (0.56) ALDH1A1MAPK1MAPTHTTITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6624157-B2 Antitumor agents BRISTOL-MYERS SQUIBB COMPANY 2003-09-23 US disclosed
US-20010039273-A1 Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase DING CHARLES Z (US) 2001-11-08 US disclosed
EP-0918771-A4 THIADIOXOBENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE BRISTOL MYERS SQUIBB CO (US) 2001-02-07 EP disclosed
EP-0918771-A1 THIADIOXOBENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE BRISTOL-MYERS SQUIBB COMPANY (US) 1999-06-02 EP disclosed
WO-1998002436-A1 THIADIOXOBENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE BRISTOL-MYERS SQUIBB COMPANY (US) 1998-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039273-A1 Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase CBR1, CBR3, FNTB ALDH1A1 3049/4885CYP1A2 294/4885CYP3A4 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.